Navigation Links
Genes May Predict Lymphoma Treatment Outcome
Date:11/26/2008

Screens might be used to determine which patients will benefit, researchers say

WEDNESDAY, Nov. 26 (HealthDay News) -- Gene activity patterns can tell doctors whether people with a certain type of non-Hodgkin lymphoma have a better chance of survival with treatment, according to a new study.

Three different signatures of gene activity, or expression -- a measure of the biological activity of a gene -- have been identified in people with diffuse large B-cell lymphoma (DLBCL). One signature, stromal-2, was linked to poor prognosis.

In studying thousands of genes in DLBCL tumors, the researchers determined that nonmalignant immune and structural cells lying near the tumor cells also have a great effect on how well patients respond to therapy.

"These biological variations are significant in patients treated with the current standard of care," study leader Dr. Louis M. Staudt of the U.S. National Cancer Institute, said in a news release issued by the organization. "Our results provide many fresh ideas about how existing drugs might be utilized to overcome the remaining resistance of some DLBCL tumors to our current therapy."

The findings were published in the Nov. 27 issue of the New England Journal of Medicine.

Diffuse large B-cell lymphoma, an aggressive type of non-Hodgkin lymphoma with several subtypes, makes up 30 percent of all newly diagnosed cases. The standard treatment for DLBCL is a combination five drugs -- cyclophosphamide, hydroxydoxorubicin (doxorubicin, Adriamycin), Oncovin (vincristine), prednisone and rituximab. Known as R-CHOP, this treatment cures up to 60 percent of patients.

Combining the new gene signature model with the International Prognostic Index (IPI), an index to predict survival of DLBCL patients based on factors such as age, stage of the tumor and spread of the cancer, improved how well both models predicted prognosis. According to the researchers, this suggests that clinical factors as well as tumor characteristics each affect the outcomes of DLBCL patients receiving treatment.

More information

The Leukemia & Lymphoma Society has more about non-Hodgkin lymphoma.



-- Kevin McKeever



SOURCE: U.S. National Cancer Institute, news release, Nov. 26, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. Traffic Fumes Plus Genes Boosts Kids Asthma Risk
3. New Database to Help Speed Search for Bipolar Disorder Genes
4. Is Perfect Pitch All in the Genes?
5. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
6. Genes Boost Risk for Rheumatoid Arthritis, Lupus
7. The genes involved in rheumatoid arthritis identified
8. If you think cancer genes are simple, you dont know JAK
9. Test for lung cancer looks for discomforting quiet among protective genes
10. Hushed Genes Might Mean Higher Lung Cancer Risk
11. EURYI project to understand how the brain wires during embryogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genes May Predict Lymphoma Treatment Outcome
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new statin, ... not known to have significant interactions with antiretroviral therapy (ART). Among people ... and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... 24, 2017 , ... Life of Purpose Treatment is proud to present “An ... held at 7:30 pm on May 10th at the University Auditorium. , This benefit ... will support the UF Collegiate Recovery Community (UFCRC). The concert will kick off the ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
(Date:4/22/2017)... San Juan Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan ... have recently released a parenting report outlining the need for summer camps to provide physical ... , The Importance of Physical Activity In Summer Camps , With an increase in specialty ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology: